Pasithea Therapeutics Corp (KTTA) Stock Price, Quote & News

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, includ...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 977 3380

Website: www.pasithea.com

Address:

1111 Lincoln Road, Suite 500, Miami Beach, United States

focafoca99 Sep. 9 at 8:43 PM

$KTTA ratified its auditor appointment and approved a reverse stock split at its annual meeting.

0 · Reply

Risky_Behavoir Sep. 8 at 3:32 PM

$KTTA reverse split coming. Get out while you can!

0 · Reply

focafoca99 Aug. 21 at 9:16 PM

$KTTA received a 180-day Nasdaq extension to regain $1 minimum bid price compliance.

0 · Reply

TI7812 Aug. 21 at 4:16 PM

$KTTA taking a flyer, sized that if it goes to zero, no problem. Looked at the chart, then asked Claude these questions: pasted the text of this PR https://seekingalpha.com/pr/20567808-pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-data and prompted Claude with: do a analyst evaluation of the risk reward to buying this stock, ticker KTTA. HC Wainwright started coverage in June 2026, PT of $3.00. I noticed some big biotech hedge funds are taking a flyer on it as of 6/30/26 SEC filing, e.g., Opaleye Mgmt w/ 2m shares (that's like a loose change you drop in panhandler paper cup) explain the trial and the cancers being treated (stage #, biology it attacks,), TAM what is this about "No events of retinal or cardiac toxicity" what do the eyes have to do with this?

0 · Reply

Mino2103 Aug. 18 at 8:22 PM

$KTTA

0 · Reply

UtahSUV Aug. 3 at 3:41 PM

$KTTA my daily fuck you to this scam

1 · Reply

UtahSUV Aug. 1 at 6:48 AM

$KTTA what a POS

0 · Reply

MrTicker Jul. 31 at 8:06 PM

$KTTA Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Opaleye Management Inc. 10K WIZARD 3:06 PM ET 7/31/2026 http://archive.fast-edgar.com/20260731/A52OS22CZW2R7TON222N2ZY2WP4IZZ22Z282 Filed on: July 31, 2026

0 · Reply

BigTimePennyStocks Jul. 12 at 9:14 PM

Small-Caps with Catalysts this week:👇👇 ( $SRXH, $NUWE, $KTTA, $NIXX, $NCPL, etc...) #NASDAQ #NYSE

3 · Reply

focafoca99 Jul. 8 at 11:19 AM

$KTTA participates in the B. Riley Mind, Muscle & Vision Summit on July 16.

0 · Reply

Pasithea Therapeutics Transcript: AGM 2026

Sep 9, 2026, 7:00 AM EDT - 4 days ago

Pasithea Therapeutics Slides: Corporate presentation

Sep 3, 2026, 4:05 PM EDT - 9 days ago

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Pasithea Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Pasithea Therapeutics Slides: Corporate presentation

Aug 7, 2026, 8:00 AM EDT - 5 weeks ago

Pasithea Therapeutics Proxy statement: Proxy filing

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Pasithea Therapeutics Proxy statement: Proxy filing

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Pasithea Therapeutics Slides: Corporate presentation

Jul 21, 2026, 7:00 AM EDT - 7 weeks ago

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Jul 8, 2026, 7:02 AM EDT - 2 months ago

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

2026-06-30T11:15:44.000Z - 2 months ago

Pasithea Therapeutics announces updated data from PAS-004 trial

Jun 30, 2026, 7:00 AM EDT - 2 months ago

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

2026-06-16T11:20:20.000Z - 2 months ago

Pasithea Therapeutics announces amendments to PAS-004 clinical study

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Jun 15, 2026, 7:02 AM EDT - 3 months ago

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference

Jun 15, 2026, 5:21 AM EDT - 3 months ago

Pasithea Therapeutics Transcript: Transcript

2026-06-02T11:30:51.000Z - 3 months ago

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

Jun 2, 2026, 7:02 AM EDT - 3 months ago

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

2026-05-29T17:55:12.000Z - 3 months ago

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

2026-05-04T11:32:53.000Z - 4 months ago

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

May 4, 2026, 7:01 AM EDT - 4 months ago

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

2026-04-20T11:26:07.000Z - 4 months ago

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

Apr 1, 2026, 7:01 AM EDT - 5 months ago

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Feb 17, 2026, 7:01 AM EST - 6 months ago

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-13T12:11:53.000Z - 8 months ago

Pasithea Therapeutics provides updated timeline on PAS-004 programs

Jan 13, 2026, 7:01 AM EST - 8 months ago

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

2025-12-08T11:15:53.000Z - 9 months ago

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-02T16:19:00.000Z - 9 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM

Dec 2, 2025, 7:00 AM EST - 9 months ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

2025-11-28T14:25:15.000Z - 9 months ago

Pasithea Therapeutics prices 80M shares at 75c in public offering

Nov 28, 2025, 9:20 AM EST - 9 months ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

2025-11-25T12:05:49.000Z - 9 months ago

Pasithea Therapeutics announces $1M award by ALS Association

2025-11-24T12:15:27.000Z - 9 months ago

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

Nov 24, 2025, 7:00 AM EST - 9 months ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

2025-11-21T17:40:13.000Z - 9 months ago

Pasithea says tablet PK exposure increases proprtionally with dose increase

Nov 21, 2025, 12:35 PM EST - 9 months ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

2025-11-21T14:02:21.000Z - 9 months ago

Why Is Pasithea Therapeutics Stock (KTTA) Down Today?

2025-11-20T21:05:17.000Z - 9 months ago

Pasithea Therapeutics announces interim data from PAS-004 trial

Nov 20, 2025, 4:01 PM EST - 9 months ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

2025-11-04T12:50:47.000Z - 10 months ago

Pasithea announces activation of trial site at UAB for study of PAS-004

Nov 4, 2025, 7:03 AM EST - 10 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

2025-09-16T11:15:43.000Z - 12 months ago

Pasithea Therapeutics announces activation of two South Korean trial sites

Sep 16, 2025, 7:03 AM EDT - 12 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

2025-09-08T11:11:03.000Z - 1 year ago

Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004

Aug 29, 2025, 8:39 AM EDT - 1 year ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 31, 2025, 7:01 AM EDT - 1 year ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jun 11, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 2, 2025, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

May 20, 2025, 7:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 14, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 7, 2025, 5:00 PM EDT - 1 year ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 1 year ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 7:03 AM EDT - 1 year ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Apr 29, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 24, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 10, 2025, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Jan 14, 2025, 8:02 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 9, 2024, 8:01 AM EDT - 2 years ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 3, 2024, 8:02 AM EDT - 2 years ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Aug 28, 2024, 9:11 AM EDT - 2 years ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

May 28, 2024, 6:59 AM EDT - 2 years ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Feb 13, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Sep 14, 2023, 8:30 AM EDT - 3 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

focafoca99 Sep. 9 at 8:43 PM

$KTTA ratified its auditor appointment and approved a reverse stock split at its annual meeting.

0 · Reply

Risky_Behavoir Sep. 8 at 3:32 PM

$KTTA reverse split coming. Get out while you can!

0 · Reply

focafoca99 Aug. 21 at 9:16 PM

$KTTA received a 180-day Nasdaq extension to regain $1 minimum bid price compliance.

0 · Reply

TI7812 Aug. 21 at 4:16 PM

0 · Reply

Mino2103 Aug. 18 at 8:22 PM

$KTTA

0 · Reply

UtahSUV Aug. 3 at 3:41 PM

$KTTA my daily fuck you to this scam

1 · Reply

UtahSUV Aug. 1 at 6:48 AM

$KTTA what a POS

0 · Reply

MrTicker Jul. 31 at 8:06 PM

0 · Reply

BigTimePennyStocks Jul. 12 at 9:14 PM

Small-Caps with Catalysts this week:👇👇 ( $SRXH, $NUWE, $KTTA, $NIXX, $NCPL, etc...) #NASDAQ #NYSE

3 · Reply

focafoca99 Jul. 8 at 11:19 AM

$KTTA participates in the B. Riley Mind, Muscle & Vision Summit on July 16.

0 · Reply

UtahSUV Jul. 2 at 2:50 PM

$KTTA the only research this company has done was to scam people from their money

0 · Reply

Aldinho_lbk Jul. 1 at 1:35 PM

$KTTA let it run... No auto stop loss...

0 · Reply

letuan7 Jul. 1 at 4:38 AM

$KTTA wow this piece of shi🌞 52 week high only $2.X 🤣🤣🤣🤣🤣 maybe .7 tomorrow if lucky

0 · Reply

letuan7 Jun. 30 at 11:54 PM

$KTTA chased .58 sold for loss chased .55 bags again piece of shit 🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️🗑️

0 · Reply

M113 Jun. 30 at 11:52 PM

$KTTA wel not the close we wanted

0 · Reply

topstockalerts Jun. 30 at 11:49 PM

After Hours Top Gainers PT2 $XTLB $CEPO $ALZN $ATXG $KTTA

1 · Reply

letuan7 Jun. 30 at 10:41 PM

$KTTA only phase 1 🤣🤣🤣🤣

0 · Reply

topstockalerts Jun. 30 at 9:33 PM

$KTTA there’s a quiet confidence to this move.

0 · Reply

Aldinho_lbk Jun. 30 at 8:22 PM

$KTTA people amazes me... This stock is a low float, have good news, and yet peice goes down because auto stop loss... Ay ay ay, tamales ..

0 · Reply

BioTuesdays Jun. 30 at 7:13 PM

$KTTA has announced updated interim safety and clinical activity data from its ongoing first-in-human trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, including those who have failed prior BRAF/MEK inhibitor treatment. https://biotuesdays.com/2026/06/30/pasithea-reports-positive-interim-phase-1-cancer-study-data/

0 · Reply

Aldinho_lbk Jun. 30 at 5:06 PM

$KTTA shoet sellers trying hard boxing up this stock... Dudes, cant you see the price is heading up?

0 · Reply

Market Cap	17.71M
Revenue (ttm)	0.00
Net Income (ttm)	-20.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	141,600
Avg Vol	269,686
Day's Range	N/A - N/A
Shares Out	33.41M
Stochastic %K	13%
Beta	0.33
Analysts	Sell
Price Target	$3.00